Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-101 in Seborrheic Keratosis
NCT01986920Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Oct 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Eskata in seborrheic keratosis (SK) (4 arms), sponsored by Aclaris Therapeutics, Inc. Primary endpoint: Physician Lesion Assessment Scale at 78 days. Started Oct 2013; status: completed.
02
Drugs
Eskata
03
Conditions
seborrheic keratosis (SK)
Beyond the preview
Go deeper on NCT01986920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01986920.